A team of U.S. senators introduced new funding legislation for a stem cell transplant program for blood disorders like sickle ...

Adults with sickle cell disease are at a high risk of having a stroke in their 30s and 40s, with lasting physical disability, ...

Care hurdles now add to the disease burden faced by U.S. sickle cell patients, despite the promise of emerging options like ...

Doctors specializing in sickle cell disease report higher levels of burnout than those not specializing in the blood disorder ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Top-line data revealed olinciguat was well-tolerated across all doses tested, but the therapy’s ...

Children’s Hospital Los Angeles (CHLA) is now offering Casgevy (exagamglogene autotemcel), an approved gene-editing therapy for sickle cell disease (SCD). “This is a transformative time for Children’s ...

Sickle cell disease (SCD) may be cured in some individuals by a stem cell transplant. There also are several approved therapies to help manage the condition and its related complications. Some of the ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Print Preferred Source on Google The Centers for Medicare & Medicaid Services (CMS) has announced ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Print Preferred Source on Google Although approximately 1 in 6 people worldwide are living with a ...

The investigational gene-editing therapy OTQ923 resulted in normalization of the speed of blood flow in the brain of three adults with sickle cell disease (SCD), according to data from a Phase 1 ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Print Preferred Source on Google Top-line data from the Phase 3 part of RISE UP, a clinical trial ...

The first participant with sickle cell disease (SCD) has been dosed in a clinical trial of HBI-002, an experimental, low-dose, oral liquid formulation of carbon monoxide being developed by Hillhurst ...